Author

Chunmei Zhang

Observed name: C. Zhang

Institution: Dali University

Observed institutions: NeoGenomics (United States), Dali University, BioMarin (United States)

ORCID: 0009-0001-0898-2518

Observed ORCID: 0009-0001-0898-2518

OpenAlex ID: A5037388001

A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

2015 · H. Roche, J. Blum, et al. · Annals of Oncology · 12

Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy

2025 · Qi Liu, Chunmei Zhang, et al. · World Journal of Surgical Oncology · 7

Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)

2025 · Qi Liu, Chunmei Zhang, et al. · Advanced Biology · 2

COX-2 Expression Correlation with Tumor-Associated Macrophages Infiltration and Prognosis in Gastric Cancer

2025 · Duo Deng, Chunmei Zhang, et al. · Research Square

Works count: 4

Citation count: 21

H-index: 2

I10-index: 1